Best Practice & Research Clinical Rheumatology
Volume 23, Issue 5 , Pages 655-664 , October 2009

Systemic JIA: new developments in the understanding of the pathophysiology and therapy

  • Sebastiaan J. Vastert, MD (Paediatric Rheumatology Fellow)

      Affiliations

    • Department of Pediatric Immunology Wilhelmina Children´s Hospital, University Medical Center Utrecht, Lundlaan 6, 3584 EA, Utrecht, the Netherlands
    • Tel.: +31 887554339; Fax: +31 887555350.
    • ,
  • Wietse Kuis, MD, PhD (Professor of Pediatrics and Head of the Department of Paediatric Rheumatology and Immunology)

      Affiliations

    • Department of Pediatric Immunology Wilhelmina Children´s Hospital, University Medical Center Utrecht, Lundlaan 6, 3584 EA, Utrecht, the Netherlands
    • Tel.: +31 887554339; Fax: +31 887555350.
    • ,
  • Alexei A. Grom, MD (Associate Professor of Pediatrics and Attending Physician)

      Affiliations

    • Division of Rheumatology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio 45229-3039, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 513 636 3339; Fax: +1 513 636 3328.

References 

  1. Still GF. On a form of chronic joint disease in children. Med-Chir Trans. 1897;80:47–59Reported Proc R Med Chir Soc 1898;9:10–15
  2. Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol. 1998;12:245–271
  3. Lang BA, et al. Radiologic features of systemic onset juvenile rheumatoid arthritis. J Rheumatol. 1995;22:168–173
  4. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 1985 Apr;106(4):561–566
  5. Ramanan AV, Schneider R. Macrophage activation syndrome–what's in a name!. J Rheumatol. 2003;30:2513–2516
  6. Athreya BH. Is macrophage activation syndrome a new entity?. Clin Exp Rheumatol. 2002;20:121–123
  7. Grom AA. NK dysfunction: a common pathway in systemic onset juvenile rheumatoid arthritis, macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Arthritis Rheum. 2004;50:689–698
  8. Filipovich HA. Hemophagocytic lymphohistiocytosis. Immunol Allergy Clin N Am. 2002;22:281–300
  9. Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemopagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–131
  10. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479–1486
  11. Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?. Rheumatology (Oxford). 2005;44:1350–1353
  12. Fall N, Barnes M, Thornton S, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007;56:3793–3804
  13. Ogilvie EM, Khan A, Hubank M, et al. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:1954–1965
  14. Frosch M, Roth J. New insights in systemic juvenile idiopathic arthritis–from pathophysiology to treatment. Rheumatology (Oxford). 2008;47:121–125
  15. Barnes MG, Grom AA, Thompson SD, et al. Gene expression signatures in new onset untreated juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:2101–2112
  16. Allantaz F, Chaussabel D, Stichweh D, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med. 2007;204:2131–2144
  17. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature. 2004;430:257–263
  18. Hull KM, Shoham N, Chae JJ, et al. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol. 2003;15:61–69
  19. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1β in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34–42
  20. Nepom BG, Glass DN. Juvenile rheumatoid arthritis and HLA: report of the Park City III workshop. J. Rheumatol. 1992;33(Suppl.):70–74
  21. Thompson SD, Moroldo MB, Guyer L, et al. A genome-wide scan for juvenile rheumatoid arthritis in affected sibpair families provides evidence of linkage. Arthritis Rheum. 2004;50(9):2920–2930
  22. Date Y, Seki N, Kamizono S, et al. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5′-flanking region of the TNFalpha gene and HLA genes. Arthritis Rheum. 1999;42:2577–2582
  23. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369–1376
  24. Ogilvie EM, Fife MS, Thompson SD, et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum. 2003;48:3202–3206
  25. Donn RP, Shelley E, Ollier WE, Thomson W. A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2001;44:1782–1785
  26. De Benedetti F, Meazza C, Vivarelli M, et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2003;48:1398–1407
  27. Wittkowski H, Frosch M, Wulffraat N, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008;58:3924–3931
  28. Frosch M, Ahlmann M, Vogl T, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:883–891
  29. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13:1042–1049
  30. Maeno N, Takei S, Imanaka H, et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum. 2004 Jun;50(6):1935–1938
  31. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?. J Rheumatol. 1998;25:203–207
  32. De Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158–1163
  33. De Benedetti F, Meazza C, Oliveri M, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology. 2001;142:4818–4826
  34. Cazzola M, Ponchio L, De BF, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood. 1996;87:4824–4830
  35. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2071–2075
  36. Irigoyen PI, Olson J, Hom C, Ilowite NT. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum. 2004;50(Suppl.):S437
  37. Henrickson M. Efficacy of anakinra in refractory systemic arthritis. Arthritis Rheum. 2004;50(Suppl.):S438
  38. Prieur AM, Kaufmann MT, Griscelli C, Dayer JM. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet. 1987;2(8570):1240–1242
  39. Gattorno M, Piccini A, Lasiglie D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505–1515
  40. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133–1138
  41. Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:965–971
  42. Avcin T, Tse SML, Schneider R, et al. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr. 2006;148:683–686
  43. Schaer DJ, Schleiffenbaum B, Kurrer M, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haemotol. 2005;74:6–10
  44. Kristiansen M, Graversen JH, Jacobsen Sonne O, et al. Identification of the hemoglobin scavenger receptor. Nature. 2001;409:198–201
  45. Porscheray F, Viaud S, Rimaniol A-C, et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol. 2005;142:481–489
  46. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–555
  47. Takahashi A, Mori M, Naruto T, et al. The role of heme oxygenase-1 in systemic onset juvenile idiopathic arthritis. Mod Rheumatol. 2009;19:302–308
  48. Stepp SE, Dufourcq-Lagelouse R, Le DF, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286:1957–1959
  49. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115:461–473
  50. zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005 Mar 15;14(6):827–834
  51. Menasche G, Pastural E, Feldman J, et al. Mutations in Rab27a cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000;25:173–176
  52. Barbosa MD, Nguyen QA, Tchernev VT, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes (LYST). Nature. 1996;382:262–265
  53. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20:129
  54. Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol. 2006;6:940–952
  55. Stepp SE, Mathew PA, Bennett M, et al. Perforin: more than just an effector molecule. Immunol Today. 2000;21:254–256
  56. Wulffraat NM, Rijkers GT, Elst E, et al. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford). 2003;42:375–379
  57. Grom AA, Villanueva J, Lee S, et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003;142:292–296
  58. Zhang K, Biroschak J, Glass DN, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008;58:2892–2896
  59. de Jager W, Hoppenreijs EP, Wulffraat NM, et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis. 2007;66:589–598
  60. Iannello A, Samarani S, Debbeche O, et al. Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells. J Virol. 2009 Jun;83(12):5999–6010
  61. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006;2:28–34
  62. Lehman TJ, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr. 2004;145:856–857
  63. Wallace CA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 1997;40:1852–1855
  64. Wulffraat NM, van Rooijen EM, Tewarie R, et al. Current perspectives of autologous stem cell transplantation for severe juvenile idiopathic arthritis. Autoimmunity. 2008;41:632–638
  65. Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol. 1991;9:297–302
  66. Speckmaier M, Findeisen J, Woo P, et al. Low-dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol. 1989;7:647–650
  67. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43:1849–1857
  68. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496–1504
  69. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–1101
  70. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638–1644
  71. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005;32:935–942
  72. Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol. 2009;36:1078–1082
  73. Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302–308
  74. Woo P. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease. Ann Rheum Dis. 2008;67:281–282
  75. Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004;4:378–385
  76. Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008;58:2432–2442
  77. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–R1288
  78. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006

PII: S1521-6942(09)00088-6

doi: 10.1016/j.berh.2009.08.003

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 5 , Pages 655-664 , October 2009

Article Tools